Violich Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Violich Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-3,100	Closed	-$226K	–	114
2019 Q3	$226K	Sell	3,100 -140	-4%	-$10.5K	0.05%	101
2019 Q2	$266K	Hold	3,240	–	–	0.07%	100
2019 Q1	$229K	Buy	+3,240	New	+$191K	0.06%	104
2018 Q3	–	Sell	-4,520	Closed	-$302K	–	117
2018 Q2	$302K	Buy	4,520 +680	+18%	+$42.5K	0.08%	93
2018 Q1	$224K	Sell	3,840 -300	-7%	-$19K	0.06%	101
2017 Q4	$267K	Hold	4,140	–	–	0.07%	96
2017 Q3	$217K	Buy	+4,140	New	+$197K	0.06%	104
2017 Q1	–	Sell	-4,020	Closed	-$255K	–	111
2016 Q4	$255K	Buy	4,020 +120	+3%	+$7.34K	0.08%	92
2016 Q3	$259K	Hold	3,900	–	–	0.09%	83
2016 Q2	$218K	Buy	+3,900	New	+$190K	0.07%	90

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Violich Capital Management's ANIP Position: Q4 2019 in Review

Violich Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2019, closing a stake of 3,100 shares — an estimated $226K sold.

Violich Capital Management first reported a position in ANIP in Q2 2016 and held it in 10 quarters. The position peaked at $302K in Q2 2018. 170 funds tracked by Wall St. Rank hold ANIP as of Q4 2019.

Violich Capital Management reported no remaining ANI Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Violich Capital Management sold 3,100 ANI Pharmaceuticals shares in Q4 2019, an estimated $226K.
Violich Capital Management first reported a position in ANI Pharmaceuticals in Q2 2016 and held it in 10 quarters.
Violich Capital Management's ANI Pharmaceuticals position peaked at $302K in Q2 2018.
170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2019.

Based on Violich Capital Management's 13F filing for Q4 2019, filed 16 Jan 2020.